reports
Collegium Pharmaceutical Inc: 1 director
A director at Collegium Pharmaceutical Inc sold 9,593 shares at 36.623USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Collegium Completes Acquisition of Ironshore Therapeutics
Collegium Completes Acquisition of Ironshore Therapeutics – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – Collegium Updates 2024 Financial Guidance to Reflect Expected Immediate Accretion from the Ironshore Acquisition – – 2024 Product Revenues, Net Expected in the Range of $620.0 Million to $635.0 Million – STOUGHTON, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it ...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investm...
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference STOUGHTON, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference being held in New York, NY from September 9-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Monday, September 9, 2024, at 12:30 p.m. ET T...
Collegium Announces Eight Poster Presentations at PAINWeek Conference ...
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024 STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that eight poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2024, being held in Las Vegas, NV, from September 3–6, 2024. “Collegium is proud to present new real-world data at PAINWeek 2024 as part of our commitment to lea...
Collegium Reports Second Quarter 2024 Financial Results
Collegium Reports Second Quarter 2024 Financial Results – Generated Q2’24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2’24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2’24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3’24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurology (ADHD) – – Reaffirmed Full-Year 2024 Guidance for the Current Business – ...
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology – Adds Commercial Product Jornay PM®, Establishing Collegium’s Presence in Neurology (ADHD) – – H1’24 Jornay PM Prescriptions Grew 32% Year-over-Year – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Acquisition Funded by Collegium’s Cash on Hand and New Five-Year Financing with Significantly Improved Terms – – Collegium Estimates Q2’24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024 Financial Guidance for the Current B...
Collegium to Report Second Quarter 2024 Financial Results on August 8,...
Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 STOUGHTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report second quarter 2024 financial results after the market closes on Thursday, August 8, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call InformationTo access the conference call, please dia...
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity fo...
Collegium Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise STOUGHTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for Nucynta® and Nucynta® ER (“the Nucynta Franchise”). In 2023, FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending the period of U.S. exclusivity from June 27, 2025...
Collegium to Participate in Jefferies Global Healthcare Conference
Collegium to Participate in Jefferies Global Healthcare Conference STOUGHTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference being held in New York, NY from June 5-6, 2024. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, June 5, 2024, at 9:30 a.m. ET The fireside chat will be webcast live and can ...
Collegium Announces $35 Million Accelerated Share Repurchase Program
Collegium Announces $35 Million Accelerated Share Repurchase Program STOUGHTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $35 million of the Company’s common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completio...
Collegium Reports First Quarter 2024 Financial Results
Collegium Reports First Quarter 2024 Financial Results – Generated Q1’24 Net Revenue of $144.9 Million – – Delivered Q1’24 Record Belbuca® Revenue of $50.7 Million; Total Prescriptions Up 4.2% Year-over-Year – – Achieved Q1’24 GAAP Net Income of $27.7 Million vs. Q1’23 GAAP Net Loss of $(17.4) Million – – Delivered Q1’24 Adjusted EBITDA of $92.4 Million, Up 5% Year-over-Year – – Board of Directors Authorized $35.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2024 Guidance – – Conference Call Scheduled for Today ...
Collegium Announces CEO Transition
Collegium Announces CEO Transition – Joe Ciaffoni to Step Down as President and Chief Executive Officer – – Board Chairman Michael Heffernan to Serve as Interim President and Chief Executive Officer – – Board of Directors has Initiated the Search for a Successor – STOUGHTON, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that effective May 24, 2024, Joe Ciaffoni will step down as President and Chief Executive Officer...
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceut...
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER STOUGHTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced it has entered into an authorized generic agreement with Hikma Pharmaceuticals USA Inc. (“Hikma”), pursuant to which Hikma will have the exclusive right to sell the authorized generic versions of Nucynta® and Nucynta® ER (“th...
Collegium to Report First Quarter 2024 Financial Results on May 9, 202...
Collegium to Report First Quarter 2024 Financial Results on May 9, 2024 STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877...
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.6...
Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026 STOUGHTON, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (the “Company”), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has called all $26,350,000 aggregate principal amount of its outstanding 2.625% Convertible Senior Notes Due 2026 (the “Notes”) (CUSIP No. 19459JAA2; ISIN No. US19459JAA25) for redemption on Friday, June 14, ...
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Con...
Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in a fireside chat at the 23rd Annual Needham Healthcare Conference being held virtually from April 8-11, 2024. Details of the event are as follows:Fireside Chat Date and Time: Wednesday, April 10, 2024, at 3:45 p.m. ET The fireside chat will be webcast liv...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XBIT XBIOTECH
UFPT UFP TECHNOLOGIES
TRIP TRIPADVISOR INC.
TPH TRI POINTE HOMES INC.
PSX PHILLIPS 66
MTRX MATRIX SERVICE COMPANY
MSA MSA SAFETY INC.
MRK MERCK & CO. INC.
ISRG INTUITIVE SURGICAL INC.
HUBB HUBBELL INCORPORATED CLASS B
GPK GRAPHIC PACKAGING HOLDING COMPANY
FRPT FRESHPET INC
FANG DIAMONDBACK ENERGY INC.
DY DYCOM INDUSTRIES INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
AL AIR LEASE CORPORATION CLASS A
ALV ALLIANZ SE
GBL GAMCO INVESTORS
CW CURTISS-WRIGHT CORPORATION
MPC. MADISON PACIFIC PROPERTIES INC. CL B
ELY CALLAWAY GOLF COMPANY
TG TREDEGAR CORP.
TAYD TAYLOR DEVICES INC.
HWKN HAWKINS INC.
FSTR L.B. FOSTER CO.
TEC TECHNIPFMC PLC
STRA STRATEGIC EDUCATION INC.
MRVI MARAVAI LIFESCIENCES HOLDINGS
SMLP SUMMIT MIDSTREAM PARTNERS
SGC ONTO INNOVATION INC.
SG CAPITAL PUBLIC COMPANY LIMITED
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
STT STATE STREET CORPORATION
C CITIGROUP INC.
XNCR XENCOR INC.
XBIT XBIOTECH
TRIP TRIPADVISOR INC.
PSX PHILLIPS 66
POST POST HOLDINGS INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
PBYI PUMA BIOTECHNOLOGY INC.
MCY MERCURY GENERAL CORPORATION
ISRG INTUITIVE SURGICAL INC.
IRM IRON MOUNTAIN INC.
HOLX HOLOGIC INC.
HMST HOMESTREET INC.
FRPT FRESHPET INC
ENSG ENSIGN GROUP INC.
DY DYCOM INDUSTRIES INC.
DVA DAVITA INC.
CRY CRYOLIFE INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ACGL ARCH CAPITAL GROUP LTD.
CW CURTISS-WRIGHT CORPORATION
MPC. MADISON PACIFIC PROPERTIES INC. CL B
ATRO ASTRONICS CORPORATION
ALPN ALPINE IMMUNE SCIENCES
TNDM TANDEM DIABETES CARE
ABT ABBOTT LABORATORIES
COOP MR. COOPER GROUP INC.
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PFC PREMIER FINANCIAL CORP
OGN ORGANON & CO
2VZ ONTO INNOVATION INC.
FIHL LEONARDO DRS INC.
FIDELIS INSURANCE HOLDINGS LIMITED
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial R...
Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results – Generated Record Quarterly and Full-Year Net Revenue of $149.7 Million and $566.8 Million – – Achieved Quarterly and Full-Year GAAP Net Income of $31.9 Million and $48.2 Million – – Delivered Record Quarterly and Full-Year Adjusted EBITDA of $104.2 Million and $367.0 Million – – Ended 2023 with Cash, Cash Equivalents and Marketable Securities of $310.5 Million – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading...
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Result...
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 STOUGHTON, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To acc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.